Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
News for Vicarious Surgical Inc. (RBOT) centers on its progress in developing the Vicarious Surgical Robotic System and on key corporate and financing events. The company describes itself as a next-generation surgical robotics and medical device developer focused on minimally invasive surgery, with a system designed for abdominal access and 3D visualization through a single port.
Recent press releases highlight development milestones such as an in-vivo porcine lab in which surgeons used the company’s pre-DV system to complete key elements of a ventral hernia repair and evaluate subsystems including instrument articulation, energy delivery instruments and visualization. These updates provide insight into how the system performs in realistic surgical environments and how data from such labs inform design refinement, verification planning and system optimization.
Investors and observers will also find news about Vicarious Surgical’s operating model and cost structure. The company has issued cash burn guidance, discussed an operational reset, and announced reductions in headcount and external consulting spend, alongside increased use of strategic outsourcing and a strategic software execution partnership with a global digital engineering firm. These items describe how Vicarious Surgical is seeking to improve execution, increase development predictability and manage operating expenses while advancing toward system design milestones.
Additional news coverage includes quarterly financial results, registered direct offerings and private placements, at-the-market offering arrangements, board and committee changes, and participation in healthcare investment conferences. Together, these updates give a view into both the technical evolution of the Vicarious Surgical System and the company’s financing, governance and investor relations activities. Readers interested in RBOT can use this page to follow ongoing disclosures about development progress, financial guidance, capital raises and corporate governance developments.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced the appointment of John Mazzola as vice president of operations. With over 30 years in the medical device industry, Mazzola aims to enhance the company’s manufacturing strategies for its next-generation surgical robotics. Prior to joining Vicarious, he held senior roles at Becton Dickinson, overseeing 10 manufacturing sites. CEO Adam Sachs expressed confidence in Mazzola's expertise to drive operational growth. Mazzola's active involvement in industry associations adds to his credentials.
Vicarious Surgical (NYSE: RBOT, RBOT WS) reported preliminary unaudited financial results for Q4 and the full year 2021. The company experienced a significant increase in operating expenses, totaling $18.2 million in Q4, up 380% year-over-year. Adjusted net loss for Q4 was $18.2 million, or $0.15 per share, compared to a loss of $3.8 million, or $0.04 per share in the prior year. Full year operating expenses reached $38.6 million, reflecting a 197% increase. Cash and cash equivalents stood at $173.5 million as of December 31, 2021.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in two upcoming virtual investor conferences. The Cowen 42nd Annual Healthcare Conference will feature a presentation on Tuesday, March 8, at 9:10 a.m. ET. Additionally, the Oppenheimer 32nd Annual Healthcare Conference is scheduled for Wednesday, March 16, at 8:40 a.m. ET. Interested parties can access live and archived presentations on the company's website. Vicarious Surgical is focused on innovative robotics technology aimed at improving surgical efficiency and patient outcomes.
Vicarious Surgical Inc. (NYSE: RBOT) will release its fourth quarter 2021 financial results on March 3, 2022, after market close. A conference call, starting at 4:30 p.m. ET, will follow to discuss the results. Investors can participate by calling 1 (646) 904 5544 domestically or +1 (929) 526 1599 internationally. Vicarious Surgical, founded in 2014, focuses on enhancing surgical efficiency and reducing healthcare costs using proprietary robotic technology.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) will engage in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16 at 4:00 p.m. Eastern Time. The company focuses on enhancing surgical procedures through next-generation robotic technology, which has been recognized by the FDA with a Breakthrough Device Designation. Founded in 2014, Vicarious Surgical aims to improve patient outcomes while reducing healthcare costs. The event is accessible via BTIG representatives.
Vicarious Surgical has been recognized with three awards in Built In’s 2022 Best Places To Work Awards, including Best Places to Work, Best Midsize Companies to Work for, and Best Paying Companies in Boston. The awards program evaluates company data on compensation and benefits, adapting to the changing needs of tech professionals. CEO Adam Sachs emphasized the company's commitment to employee success as it grows. Founded in 2014, Vicarious Surgical focuses on innovative surgical robotics and has received Breakthrough Device Designation from the FDA for its technology.
Summary not available.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The presentation will be accessible from November 22, 2021, at 10:00 a.m. Eastern Time on their website. Founded in 2014, Vicarious Surgical is innovating surgical procedures using advanced robotics and virtual reality technology, aiming to enhance efficiency and patient outcomes. Their technology is recognized with Breakthrough Device Designation by the FDA, marking a significant milestone in surgical robotics.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its third quarter 2021 financial results, marking its entry into public markets. The company posted an operating expense of $8.6 million, a 156.2% increase from the previous year. R&D expenses rose to $5.2 million while general and administrative costs increased to $2.5 million. The net loss reached $65.5 million, showing a significant increase from $3.3 million in Q3 2020, resulting in a net loss per share of $0.71. However, cash reserves stood strong at $185 million as of September 30, 2021.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) will present at the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on November 18 at 4:00 p.m. Eastern Time. The management will also engage in virtual investor meetings throughout the day. The presentation will be live-streamed on the Company’s website, with an archive available afterward. Vicarious Surgical specializes in innovative robotics technology aimed at enhancing surgical efficiency and patient outcomes.